X
Healthcare Mar 14, 2022 09:38 AM (GMT+8) · EqualOcean
On March 14, Shanghai yuesai Biotechnology Co., Ltd. (hereinafter referred to as "yuesai biology"), a leading enterprise committed to developing pluripotent stem cell drugs, announced that it had completed nearly 200 million yuan of financing. This round of financing is led by Sherpa investment, jointly led by CDH VGC (innovation and Growth Fund), and jointly invested by Taifu capital, Kunlun capital, Gaoling venture capital, Fosun Pharmaceutical, Ruihua capital and national capital. This round of financing will be mainly used for the R & D investment of multiple pipelines, the construction of clinical cell product production plants, and the start and promotion of relevant clinical trials. Yuesai biology, founded in June 2021, is a company focusing on the development of a new generation of cell therapy drugs based on human pluripotent stem cell technology. It aims to use the technology platform of human pluripotent stem cell preparation, culture, differentiation and gene editing, and is committed to technology research and development and product development in the field of stem cell therapy. Its R & D pipeline covers neurodegenerative diseases, rare diseases and tumors.

This text is a result of machine translation.